- Home
- NPKI vs AUTL Comparison
NPKI vs AUTL Comparison
Compare NPKI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPKI | AUTL |
|---|---|---|
| Founded | 1932 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 433.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NPKI | AUTL |
|---|---|---|
| Price | $12.11 | $1.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $14.17 | $8.33 |
| AVG Volume (30 Days) | 661.0K | ★ 2.4M |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $259,372,000.00 | $51,128,000.00 |
| Revenue This Year | $26.96 | $669.49 |
| Revenue Next Year | $13.16 | $91.53 |
| P/E Ratio | $31.90 | ★ N/A |
| Revenue Growth | 25.65 | ★ 406.67 |
| 52 Week Low | $4.76 | $1.11 |
| 52 Week High | $14.00 | $2.80 |
Technical Indicators
Market Signals| Indicator | NPKI | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 57.88 |
| Support Level | $12.21 | $1.63 |
| Resistance Level | $12.57 | $1.79 |
| Average True Range (ATR) | 0.35 | 0.09 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 13.57 | 59.09 |
Price Performance
Historical ComparisonAbout NPKI NPK International Inc.
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.